Diazonium‐Enabled Post‐Synthetic Construction of Enantiomeric Single‐Atom Nanoagents Used for Alzheimer's Disease Treatment
Small · 2026
DOI: 10.1002/smll.74610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2026. Verfasst von Junlin Ya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy…. Hauptthemen laut MEDLINE: Alzheimer Disease, Diazonium Compounds. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Science and Technology Major Project.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is driven by a self‐amplifying interplay between oxidative stress and neuroinflammation, in which mitochondrial DNA (mtDNA) leakage‐induced activation of the cGAS‐STING pathway plays a central role. Strategies that solely eliminate reactive oxygen species (ROS) are insufficient to suppress downstream inflammatory cascades. Here, we report a pair of chiral dual‐functional single‐atom nanoagents that can simultaneously scavenge ROS and sequester leaked mtDNA. A diazonium‐enabled post‐synthetic modification strategy is employed to graft benzoic acid linkers onto a single‐atom catalyst, enabling covalent conjugation of nona‐arginine peptides with opposite chirality (L‐/D‐R9). The resulting constructs are further encapsulated by KLVFFAED peptides and tannic acid to yield L‐/D‐TKRM, conferring blood‐brain barrier permeability and mitochondrial targeting. Both L‐ and D‐TKRM effectively scavenge ROS and preserve mitochondrial function in Aβ‐stimulated microglia, while D‐TKRM exhibits enantioselectively prolonged mtDNA capture, more efficient suppression of cGAS–STING signaling, enhanced M2 microglial polarization, and superior neuroprotection. In vivo studies have demonstrated that these two nanoagents rescue cognitive function in 3 × Tg‐AD mice, with D‐TKRM showing better efficacy accompanied by reduced amyloid pathology, microglial activation, and neuronal loss. This work highlights diazonium chemistry as a new, versatile single‐atom functionalization strategy and underscores that chirality is important for developing effective therapeutic agents for AD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, Anhui, China.
- State Key Laboratory of Electroanalytic Chemistry, Jilin Province Key Laboratory of Low Carbon Chemistry Power, Jilin Provincial Science and Technology Innovation Center of Hydrogen Energy, Changchun Institute of Applie…
ORCID-Profile: Jinsong Ren, Xiaogang Qu
Förderung
- National Natural Science Foundation of China
- National Science and Technology Major Project
Zitieren
APA
Ya, J., Liu, M., Ji, Y., Tong, Z., Luo, B., Bai, J., Ren, J., & Qu, X. (2026). Diazonium‐Enabled Post‐Synthetic Construction of Enantiomeric Single‐Atom Nanoagents Used for Alzheimer's Disease Treatment. Small. https://doi.org/10.1002/smll.74610
Vancouver
Ya J, Liu M, Ji Y, Tong Z, Luo B, Bai J, et al. Diazonium‐Enabled Post‐Synthetic Construction of Enantiomeric Single‐Atom Nanoagents Used for Alzheimer's Disease Treatment. Small. 2026. doi:10.1002/smll.74610
BibTeX
@article{Ya2026,
author = {Ya, Junlin and Liu, Mengmeng and Ji, Yanjun and Tong, Zhibo and Luo, Bin and Bai, Jingsen and Ren, Jinsong and Qu, Xiaogang},
title = {Diazonium‐Enabled Post‐Synthetic Construction of Enantiomeric Single‐Atom Nanoagents Used for Alzheimer's Disease Treatment},
journal = {Small},
year = {2026},
doi = {10.1002/smll.74610}
}
EUVIMED